Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Vulvodynia Treatment Drug Market size was estimated at over USD 6.9 billion in 2024 and is poised to reach USD 15.2 billion by the end of 2037, exhibiting a CAGR of 6.8% during the forecast period. In 2025, the industry size of the vulvodynia treatment drug is evaluated at USD 7.3 billion.
The market is experiencing immense growth fueled by the increasing awareness of chronic pelvic pain disorders among women across the world and the rising demand for chronic pain management solutions. Moreover, these concerns require advanced neuro-modulating drugs, antidepressants, and topical treatments to alleviate the symptoms, further augmenting the industry expansion.
In addition, the rising prevalence of vulvodynia among women worldwide is the key factor driving growth in this sector. In this regard, according to a clinical study by NLM in March 2025, the annual incidence of vulvodynia was 3.1% in a year. It further found a point of prevalence of 8.3% to 10.7% among reproductive-aged women. By the age of 40, 7% of women in the U.S. experience symptoms of vulvodynia. Thus, growing cases are concerning the public healthcare associations, pushing them to invest in emphasizing effective treatments, solidifying their positions in the market landscape of this sector.
Vulvodynia Treatment Drug Sector: Growth Drivers and Challenges
Growth Drivers
- Rising consciousness and diagnosis of pelvic pain concerns: One of the major factors driving growth in the vulvodynia treatment drug market is the acknowledgement of pelvic floor disorders in women. Due to the increasing focus and recognition of this condition, there are public health campaigns, initiatives to educate women for an earlier diagnosis. As per the EJOGRB study published in September 2020, analyzing 1183 patients experiencing vulvar pain, 323 were found to be diagnosed with vulvodynia, which is 27.3 %. It further stated that women experiencing severe vulvar pain must undergo diagnostic tests, thereby augmenting market growth with positive outcomes.
- Increasing women’s health research and drug development: One of the exceptional supports for the market is the growing investment in women’s health research and innovations in drug development. The proactive research initiatives aim to mitigate issues with side effects and develop new, more effective formulations. In January 2024, Knight Therapeutics Inc. launched IMVEXXY (estradiol vaginal inserts) in Canada approved for the treatment of postmenopausal dyspareunia which is a symptom of vulvar and vaginal atrophy. The availability of such indicators further encourages organizations to launch more such products, supporting the vulvodynia treatment drug market growth.
Challenges
- Limited treatment success: One of the primary challenges posed by the vulvodynia treatment drug market is the persistent lack of success in vulvodynia treatment procedures. The limited effectiveness of current therapeutic options hinders the expansion of this sector. In addition to the volatility in general availability of these drugs often face pricing issues and poor outcomes, making it hard for patients to adopt. Moreover, these low success rates may dominate the limited budget of price-sensitive hospitals, restricting product exposure across the healthcare industry.
- Social stigma: Despite having limited adverse reaction cases, growth in the vulvodynia treatment drug market can be hindered due to social stigma, and patients are often misdiagnosed by medical professionals. The sensitive nature of vulvar pain and a general lack of awareness among healthcare providers often contribute to the restraint. This may further create a hurdle for this sector to capture the optimum consumer base in the women’s health industry. Moreover, this highly sensitive field can bring uncertainty in profit-making and consistent growth.
Vulvodynia Treatment Drug Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.8% |
|
Base Year Market Size (2024) |
USD 6.9 billion |
|
Forecast Year Market Size (2037) |
USD 15.2 billion |
|
Regional Scope |
|
Vulvodynia Treatment Drug Segmentation
Drug Class (Anticonvulsants, Local Anesthetics, Tricyclic Antidepressants, Serotonin-norepinephrine Reuptake Inhibitors (SNRIs))
Based on drug class, the anticonvulsants segment is expected to garner the highest share of 39.2% in the vulvodynia treatment drug market by the end of 2037. The dominance of the segment is attributable to its capability in managing seizures, relieving symptoms by regulating nerve signals. According to the December 2022 NLM report, anticonvulsants such as gabapentin are frequently used for vulvar pain treatment, demonstrating higher efficacy in reducing painful sensations. Thus, these findings support further investigation into anticonvulsants as a promising drug class, further driving demand, inspiring pharma companies to introduce more of these formulations.
Route of Administration (Oral, Topical, Injectable)
Based on route of administration, the oral segment is projected to account for a lucrative share in the vulvodynia treatment drug market during the forecast period. The segment is pledged to growing usage of oral medications as a convenient dosing for patients diagnosed with the disease. As per the Case Reports in Women's Health study published in March 2025, the low-dose naltrexone has showcased promising results for vulvodynia treatment in patients with persistent pain and no side effects. In all three case series, postmenopausal women reported symptom relief with vulvodynia affecting up to 9.4% of the U.S. women aged 18-70. Hence, it makes the vulvodynia drugs preferable, inspiring companies to develop more effective solutions.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportVulvodynia Treatment Drug Industry - Regional Synopsis
North America Market Analysis
The North America vulvodynia treatment drug market is anticipated to hold the highest share of 35.5% during the forecast period. The dominance in the region is attributable to the supportive reimbursement notions and approvals from the regulatory framework for women's health drugs. For instance, in August 2022, SCYNEXIS, Inc. declared that it received the U.S. FDA acceptance and review for BREXAFEMME (ibrexafungerp) for preventing cyclical vaginal yeast infections such as vulvovaginal candidiasis. This highlights the growing adoption for advanced vaginal therapeutics thereby uplifting market progression.
The U.S. has become the hub for global leaders in the vulvodynia treatment drug market due to its wide consumer base and excellent manufacturing channels. The country hosts a substantial number of key players, which further inspires it to establish more of such hubs, propelling market growth. In April 2025, Peptonic Medical AB launched a new subsidiary, Peptonic Medical Inc., in the U.S. to handle direct sales of its intimate health products that is existing and new launches by creating a clear connection between Nordiac operations and U.S. activities. Thus, a positive outlook for market progression.
Canada is steadily consolidating its position in the vulvodynia treatment drug market with proactive government initiatives and launch activities. The concerning growth in vulvodynia cases is pushing the players to promote available treatment procedures. For instance, in March 2021, Lupin Pharma, in partnership with Endoceutics, Inc., announced that it had commercialized INTRAROSA in Canada, utilized for the treatment of postmenopausal vulvovaginal atrophy, which is generally provided as vaginal ovule consisting 6.5 mg of prasterone. This is further inflating demand in this sector due to the proven efficacy of such therapeutics in treating women's health conditions.
APAC Market Statistics
Asia Pacific is expected to demonstrate the fastest growth in the vulvodynia treatment drug market with its strong capacity in pharmaceuticals and ongoing research activities. The growth in the region is characterized by the immense awareness about women’s health concerns and the development of exclusive, efficacious drugs to elevate their production and launch across the world. Moreover, the governing bodies in the region are highly supportive of non-invasive procedures and personalized medicine. Therefore, such factors are driving innovations in this field, thereby uplifting market expansion.
India is propagating the regional vulvodynia treatment drug market with its strong pharmaceutical sector and expansion. The country leverages accessibility to a wide range of therapeutic drugs to mitigate the rising burden of vulvodynia among the female population in India. For instance, in February 2022, Lupin Pharmaceuticals Inc. received the U.S. FDA clearance for its expanded use of SOLOSEC (secnidazole) to treat bacterial vaginosis and trichomoniasis in female patients 12 years and above. This regulatory support from authorities is fueling this sector, inspiring the international players to establish their footprint in India.
China is one of the biggest players vulvodynia treatment drug market, which is emerging as a great distribution source of this region. The country is also aiming to introduce more of such solutions through mass production, offering a favorable business environment for both domestic and international players. In April 2025, Mycovia Pharmaceuticals, Inc., in partnership with Jiangsu Hengrui Pharmaceuticals Co., Ltd, notified that VIVJOA (Oteseconazole) capsule is now included in the CNDL by China’s National Healthcare Security Administration for treating severe vulvovaginal candidiasis. Such moves are significantly impacting vulvodynia treatment drug market expansion during the forecast period.
Companies Dominating the Vulvodynia Treatment Drug Landscape
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Allergan plc
- Cadila Pharmaceuticals
- Peptonic Medical AB
- Organon & Co.
- AFT Pharmaceuticals
- Hyloris Pharmaceuticals
- Mycovia Pharmaceuticals, Inc
- Jiangsu Hengrui Pharmaceuticals Co., Ltd
- Lupin Pharmaceuticals Inc
- SCYNEXIS, Inc.
- Knight Therapeutics Inc
The competitive demographic of the vulvodynia treatment drug market is inspiring global leaders to allocate their research resources to innovating more effective solutions. This is drawing the focus of other pharmaceutical firms to participate, enlarging the boundaries of this sector. For instance, in January 2024, AFT Pharmaceuticals, in partnership with Hyloris Pharmaceuticals, declared that it is developing a holistic treatment procedure with HY-091 for Vulvar Lichen Sclerosus, which has very narrow approved procedures available. This underscores the growing interest in urogenital female health, encouraging the key players to offer complementary solutions to maintain vaginal balance.
Such key players include:
In the News
- In January 2025, Peptonic Medical AB notified that the U.S. Patent and Trademark Office has granted a patent for the relief of vulvodynia, which is valid up to April 2041 and is ready to be launched in the U.S.
- In January 2024, Organon & Co. notified that its XACIATO (clindamycin phosphate) which is a vaginal gel 2% to treat bacterial vaginosis (BV) in women aged 12 and above is accessible with prescription that can be applied regardless the time.
- In June 2021, Organon & Co. announced the launch of a global women’s health firm by putting together women and employees across the globe to address the challenges in women’s health.
Author Credits: Radhika Pawar
- Report ID: 7629
- Published Date: May 09, 2025
- Report Format: PDF, PPT
